Merck’s strategic dealmaking escalates with MoonLake Immunotherapeutics bid as the looming Keytruda patent expiry approaches. In a recent agreement with Hercules Capital, MoonLake secured up to $500 million in non-dilutive capital, with an initial $75 million drawdown and additional tranches tied to specific milestones aligning with MoonLake’s strategic objectives and financial requirements. This move signifies […]